International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2717-2721 www.ijprajournal.com ISSN: 2456-4494

"The Drug Approval Process: A Comparative Analysis between Global Regulatory Agencies"

Prof. (Dr.) Mohd. Wasiullah[1], Prof. (Dr.) Piyush Yadav[2], Sushil Yadav[3]*, Rahul Nishad[4].

Date of Submission: 25-04-2025 Date of Acceptance: 05-05-2025

ABSTRACT:
The drug approval process is essential for ensuring the safety, efficacy, and quality of medicines worldwide. This comparative analysis examines the approaches of three prominent regulatory agencies: the U.S. FDA, the European Medicines Agency (EMA), and India's CDSCO. The FDA is characterized by its rigorous, evidence-based process, while the EMA employs a centralized system that promotes collaboration across the European Union. India's CDSCO focuses on expedited approvals for generic drugs and affordability, addressing domestic healthcare demands. Differences in approval timelines are notable—the FDA emphasizes thoroughness, the EMA offers conditional approvals for urgent cases, and the CDSCO prioritizes speed and accessibility. This study highlights the interplay between regulatory strategies and socio-economic factors, uncovering opportunities for global harmonization. By fostering efficiency, innovation, and equity, regulatory agencies can better address emerging healthcare challenges and improve access to life-saving treatments worldwide.

Keyword: The process for approving drug in India, Principle difference between U.S. ,Europe and India, Administrative Requirements, Finish product controle system , Stability requirements.

I. INTRODUCTION

The topic "Comparative Analysis of Global Drug Approval Processes" examines the diverse regulatory frameworks and methodologies employed by different countries to evaluate and approve pharmaceutical drugs. This analysis is essential for understanding the variations in approval timelines, documentation requirements, and regulatory standards across regions such as the United States, Europe, and India. Each region has its own regulatory authority—like the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO)—which operates within unique legal, cultural, and healthcare landscapes.

In the United States, the drug approval process is known for its rigorous standards, requiring extensive clinical trials and data submission through applications like the Investigational New Drug (IND) and New Drug Application (NDA). The European Medicines Agency, on the other hand, offers multiple pathways for drug approval, including the centralized procedure, which allows for a single application to market a drug across all EU member states.

DRUG APPROVAL PROCESS IN DIFFERENT CONTRIES

The process for approving drugs in India:

The Drugs and Cosmetics Act 1940 and Rules 1945 were passed to regulate the import, manufacture, distribution, and sale of drugs and cosmetics. The drug approval procedure is controlled in India by the Central Drugs Standard Control Organization (CDSCO). CDSCO is headed by the Drugs Controller General of India (DCGI). DCGI works under the Ministry of Health (MOH) and is in New Delhi. The Drug and Cosmetics Rules of 1945 received Schedule Y from the Indian government in 1988. The rules and specifications for clinical trials are contained in Schedule Y, which was further reviewed in 2005 to bring it into compliance with accepted international practice. To produce or import a novel drug in India, a company must submit Form 44 together with the information required under Schedule Y of the Drugs and Cosmetics Act 1940 and Rules 1945 in order to request approval from the licensing body (DCGI).

Rule:
For an investigational new drug, the sponsor needs to provide detailed information to the DCGI about:

- Generic name
- Patent status

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2717-2721 www.ijprajournal.com ISSN: 2456-4494

- Brief description of Physio-chemical
- Biological
- Technical information
- Stability
- Specifications
- Manufacturing process
- Worldwide regulatory status
- Animal pharmacology and toxicity studies
- Published clinical trial reports
- Proposed protocol and pro forma
- Trial duration
- During the expert file
- Undertaking to Report Serious or Life-threatening Adverse Drug Reactions.
- Clinical study approval in India typically takes three months. The Clinical Studies Registry of India (CTRI) is the place where clinical trials can be registered, with information about the trials and the participant



Fig. 1: The Drug Approval Process in India

The rules to be followed under The Drugs and Cosmetics Rules 1945 are:

Rule 122 - A: Application for permission to import new drug.

Rule 122- B: Application for approval to manufacture new drugs other than the drugs specified under Schedule C and C1.

Rule 122 - D: Permission to import or manufacture fixed dose combination.

Rule 122 - DA: Application for permission to conduct clinical trials for New Drug.

Rule 122 - DAB: Compensation in the case of injury or death during clinical trials.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2717-2721 www.ijprajournal.com ISSN: 2456-4494

COMPARISION BETWEEN US, EUROPE and INDIA

Table 1: PRINCIPLE DIFFERENCE BETWEEN US, EUROPE, and INDIA

Sr. N.	REQUIREMENTS	US	EU	INDIA
1.	Agency	One-Agency **USFDA**	Multiple Agencies • **EMEA** • **CHMP** • **National Health Agencies**	One Agency **DCGI**
2.	One Registration Process	One-registration process	Multiple registration process • Centralized(European community) • Decentralized (at least 2 member states) • Mutual recognition (at least 2 member states) • National (1 member state)	One registration process
3.	TSE/BSE Data study	Not Required	Required	Required
4.	Braille code	Braille code is Required on labelling	Braille code is required for labelling	Braille code is not required on labelling
5.	Post -Approval changes	Post-approved changes in the approved drug: • Minor • Moderate • Major	Post variation in the approved drug: • Type IA • Type IB • Type II	Post-approval changes: • Major • Moderate

Table 2: ADMINISTRATIVE REQUIREMENTS

Requirements	US	EU	INDIA
Application	ANDA/NDA	MAA	MAA
Deoartment classification	Required	Not required	Not required
Number of Copies	3	1	1
Approcal Timeline	18 Months	12 Months	2-18 Months
Fees	Under-$2million application-$1,520 million – application A	National fee (including hybrid application): £103,059 Decentralized procedure where UK is CMS: £99,507	50,000 INR
Presentation	eCTD and Paper	eCTD	Paper

Table 4: FINISHED PRODUCT CONTROL SYSTEM

Requirements	US	EUROPE	INDIA
Justification	ICH Q6A	ICH Q6A	ICH Q6A
Assay	90 – 100 %	95 – 105 %	90 – 110 %
Disintegration	Not required	Required	Required
Colour Identification	Not required	Required	Required
Water Content	Required	Not required	Required

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2717-2721 www.ijprajournal.com ISSN: 2456-4494

Table 5: STABILITY REQUIREMENTS

Requirements	US	EUROPE	INDIA
Number of Batches	3 Pilot Batch or 2 Pilot Batch & 1 Small scale	2 Pilot Scale (If API stable) 3 Primary Batches (If API unstable)	2-Pilot Scale/Production scale (If API stable) 3Primary Batches (If API unstable)
Condition:Long-term stability,Accelerated stability	Long-term: 25°C/65%RH Accelerated:40°C/75% RH(0,3,6 months)Intermediate: 30°C/65%RH	Long-term: 25°C/65%RH Accelerated: 40°C/75%RH(0,3,6,months)Intermediate:30°C/65%RH	Long-term: 30°C/70%RH Accelerated:40°C/75%RH(0,3,6months)
Minimum-Time period for submission	6-months accelerate & 6 months long term	6-months accelerate & 6 months long term	6-months accelerate & 6 months long term
Container Orientation	Inverted & Upright	Do not address	Inverted & Upright
Clause	21 CFR part 210 & 211	Volume 4 EU Guidelines for medicinal products	ICH Q1F
QP Certificato-n	Not Required	Required	Required

II. CONCLUSION

The drug approval process is a critical aspect of ensuring the safety, efficacy, and quality of pharmaceuticals before they reach the market. While the fundamental goal remains consistent across regions, the procedures and regulatory frameworks differ significantly between the United States, Europe, and India. Here's a comprehensive conclusion on the topic:

The United States, Europe, and India each have distinct regulatory systems for drug approval, shaped by their unique healthcare needs, legal frameworks, and market dynamics. The United States Food and Drug Administration (FDA) is renowned for its stringent standards and rigorous evaluation processes. It emphasizes extensive preclinical and clinical trials, ensuring that drugs meet high safety and efficacy benchmarks. The FDA's centralized approach streamlines the approval process, making it efficient but demanding for pharmaceutical companies.

In Europe, the European Medicines Agency (EMA) oversees drug approvals, employing a decentralized system that accommodates the diverse healthcare systems of its member states. The EMA offers multiple pathways for approval, including centralized, decentralized, and mutual recognition procedures. This flexibility allows pharmaceutical companies to tailor their approach based on the target markets within Europe. The EMA's focus on harmonization and collaboration among member states ensures consistency in drug evaluation while respecting regional differences.

India's drug approval process, governed by the Central Drugs Standard Control Organization (CDSCO), reflects the country's evolving healthcare landscape. While India has made significant strides in strengthening its regulatory framework, challenges such as resource constraints and varying standards across states persist. The CDSCO emphasizes affordability and accessibility, aligning with India's goal of providing cost-effective healthcare solutions to its population. However, the process is often criticized for its lack of transparency and consistency compared to the FDA and EMA.

A comparative analysis reveals that the FDA's rigorous standards and centralized approach make it a global benchmark for drug approval. The EMA's decentralized system offers flexibility and regional adaptability, catering to the diverse needs of Europe. India's CDSCO, while focused on affordability, faces challenges in achieving the same level of rigor and transparency as its Western counterparts.

REFERENCES

[1]. Mr. Shree Krishna Salunke[1], Ms. Sonal. S. Shinde[2]. A Review on Regulatory Affairs. International Journal of Research

Publication and Reviews 2022 June; 3(6):4536- 4550.
[2]. Dr. Wanjari B.E, Khalode K.K, Bhendarkar K.B, Rangari M.N, "A Text Book of Pharmaceutical Regulatory Science", Published by Aditi Publication Raipur, Chhattisgarh, India,
[3]. Sonali P. Mahaparale and Bhakti R. Desai. Role and overview of drug regulatory affairs in the pharmaceutical industry with the implementation of CTD and ECTD. World Journal of Pharmaceutical Research 2018 March 21; 7(7):201-215. doi: 10.20959/wjpr20187-11267
[4]. Shah C., Dave P. Regulatory Approval in India: An updated review, Applied clinical trials 2016 May 04.
[5]. Preeti Maan Singh, Shilpa Pahwa, Sheetl Chaudhary & Vandana Arora Sethi. New Drug Approval Procedure in Different Countries: A Review. International Journal of ChemTech Research 2017; 01-21.
[6]. Europe, and India. Journal of Pharmaceutical Science and Research 2017; 9(10):1943-1952.
[7]. Sawant AM, Mali DP and Bhagwat DA, Regulatory Requirements and Drug Approval Process in India, Europe and US. Pharmaceutical Regulatory Affairs 2018 Dec;7(2). doi: page 21-76
[8]. Ali A, Ali J, Sahni JK, Qureshi J. United States of America. In: International Licensing. New Delhi: Hamdard University, Excel Books Pvt Ltd 2007; pp. 51- 110.
[9]. Randall B IV. The U.S. Drug Approval Process: A Primer; Congressional Research Service; The Library of Congress 2001June 1. Page-52-70
[10]. William RP, Raymond DM. Drug Regulatory Affairs. In: Lachman L, Lieberman HA, The theory, and practice of Industrial Pharmacy. India: CBS Publishers and Distributors 2009; pp. 856-882.
[11]. Peck GE, Poust R. Food and Drug Laws that affect Drug Product Design, Manufacture, and Distribution. In: Gilbert SB, Christopher TR, Modern Pharmaceutics. 4th ed, New York: Marcel Dekker Inc 2002; pp. 930-46.
[12]. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc.; 2008;201-202
[13]. IRA RB, Robert PM. The Pharmaceutical Regulatory Process. 2nd ed. Informa Healthcare; 2008. p. 45-46.
[14]. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc.; 2008. p. 203- 210.
[15]. Rick N.G., Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 215- 217
[16]. Anjan K. Mahapatra1,N.H. Sameeraja1 and P.N. Murthy2. Drug Approval Process – In United States of America, European Union, and India: A Review. Bentham Science Publishers 2014,13-22
[17]. European Commission. The Rules governing Medicinal Products in the European Community; Volume 2A; Chapter 1; Marketing Authorisation; Available from: http://ec.europa.eu/health/files/EudraLex/vol - 2/a/vol2a_chap1_2013-06_en.pdf.
[18]. Regulatory requirements. Timeline for approval [Internet]. 2005 [Cited 2018 Feb 02]. Available from: www.clinpage.com/article/indias_regulation _timeline/C9.
[19]. Technical Guidance on the Development of In-vitro Companion Diagnostics and Corresponding therapeutic Products [Internet]. PMDA; 2013 Dec 26 [Cited 2018 Jan 10]. Page-23-34.
[20]. Bolar H, Bhatt A. India. In: Chambers AA, International Pharmaceutical Registration. Florida: CRC Press LLC 2000;193-203.
[21]. Bolar H, Bhatt A. India. In: Chambers AA, International Pharmaceutical Registration. Florida: CRC Press LLC 2000;193-203.
[22]. Bhatt A. Clinical trials in India: Pangs of globalization. Indian J Pharmacol [serial online] 2004 [cited 2023 Mar 17], 20-26.
[23]. Dr. Wanjari B.E, Khalode K.K, Bhendarkar K.B, Rangari M.N, "A Text Book of Pharmaceutical Regulatory Science", Published by Aditi Publication Raipur, Chhattisgarh, India,
[24]. Jawahar.N , Vidhya Lakshmi. T, Regulatory Requirements for the Drug Approval Process in the US,
[25]. Pisano DJ, David M. Overview of Drug Development, and the FDA. In: Pisano DJ, FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics. Florida: CRC Press LLC 2004; 2-20.